Logo image of BHST

BIOHARVEST SCIENCES INC (BHST) Stock News

NASDAQ:BHST - Nasdaq - CA09076J2074 - Common Stock - Currency: USD

6.3933  -0.16 (-2.39%)

BHST Latest News, Press Relases and Analysis

News Image
5 hours ago - Zacks Investment Research

Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -12.50% and 3.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: ADMA

News Image
a day ago - Zacks Investment Research

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of -28.46% and 17.12%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: DNA

News Image
a month ago - Zacks Investment Research

BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -41.67% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Mentions: MDXG

News Image
2 months ago - Benzinga

EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest's First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

BioHarvest's olive cell compound, rich in Verbascoside, showed promising results in reducing fat accumulation in liver cells, with a 2026 market launch planned.